Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 May 1:13:3-19.
doi: 10.2217/fmb-2017-0289.

Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates

Affiliations
Free article
Comparative Study

Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates

Rafael Canton et al. Future Microbiol. .
Free article

Abstract

Aim: To compare the in vitro activity of the anti-impetigo agent, ozenoxacin, and other antimicrobial agents against Gram-positive clinical isolates from skin and soft tissue infections.

Materials & methods: Isolates were collected in two studies: 1097 isolates from 49 centers during 2009-2010 and 1031 isolates from ten centers during 2014. Minimum inhibitory concentrations were determined for 18 and 11 antimicrobials in these studies, respectively, using standard broth microdilution methods. Isolates were stratified by species and methicillin susceptibility/resistance and/or levofloxacin susceptibility/nonsusceptibility status.

Results: Ozenoxacin exhibited high in vitro activity against Staphylococcus aureus and coagulase-negative staphylococci isolates in both studies. Ozenoxacin was also highly active against Streptococcus pyogenes and Streptococcus agalactiae isolates.

Conclusion: Ozenoxacin is a potent antimicrobial agent against staphylococci and streptococci.

Keywords: Gram-positive; MRSA; antibacterial activity; clinical isolates; ozenoxacin.

PubMed Disclaimer

Publication types

MeSH terms